(VIANEWS) – SCYNEXIS (SCYX), Amphastar Pharmaceuticals (AMPH), Humana (HUM) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SCYNEXIS (SCYX)
285.2% sales growth and 64.05% return on equity
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, SCYNEXIS has a trailing twelve months EPS of $0.85.
PE Ratio
SCYNEXIS has a trailing twelve months price to earnings ratio of 2.21. Meaning, the purchaser of the share is investing $2.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 64.05%.
2. Amphastar Pharmaceuticals (AMPH)
36.7% sales growth and 18.73% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $1.94.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 23.34. Meaning, the purchaser of the share is investing $23.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.73%.
Moving Average
Amphastar Pharmaceuticals’s value is under its 50-day moving average of $47.97 and above its 200-day moving average of $44.88.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Amphastar Pharmaceuticals’s EBITDA is 73.58.
Sales Growth
Amphastar Pharmaceuticals’s sales growth is 45.4% for the ongoing quarter and 36.7% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18%, now sitting on 540.89M for the twelve trailing months.
3. Humana (HUM)
13.7% sales growth and 18.04% return on equity
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, life insurance, and other supplemental health benefits, as well as administrative services only products to individuals and employer groups; military services, such as TRICARE T2017 East Region contract; and engages in the operations of PBM business. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Earnings Per Share
As for profitability, Humana has a trailing twelve months EPS of $24.18.
PE Ratio
Humana has a trailing twelve months price to earnings ratio of 20.09. Meaning, the purchaser of the share is investing $20.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.04%.
Volume
Today’s last reported volume for Humana is 611737 which is 38.5% below its average volume of 994768.
4. Southwest Airlines (LUV)
9.5% sales growth and 4.52% return on equity
Southwest Airlines Co. operates as a passenger airline company that provide scheduled air transportation services in the United States and near-international markets. As of December 31, 2022, the company operated a total fleet of 770 Boeing 737 aircrafts; and served 121 destinations in 42 states, the District of Columbia, and the Commonwealth of Puerto Rico, as well as ten near-international countries, including Mexico, Jamaica, the Bahamas, Aruba, the Dominican Republic, Costa Rica, Belize, Cuba, the Cayman Islands, and Turks and Caicos. It also provides inflight entertainment portal and connectivity services on Wi-Fi enabled aircrafts; and Rapid Rewards loyalty program that enables program members to earn points for dollars spent on Southwest base fares. In addition, the company offers a suite of digital platforms to support customers' travel needs, including websites and apps; and SWABIZ, an online booking tool. Further, it provides ancillary services, such as Southwest's EarlyBird Check-In, upgraded boarding, and transportation of pets and unaccompanied minors. The company was incorporated in 1967 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Southwest Airlines has a trailing twelve months EPS of $0.81.
PE Ratio
Southwest Airlines has a trailing twelve months price to earnings ratio of 29.04. Meaning, the purchaser of the share is investing $29.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.52%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 24% and positive 192.1% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Sep 4, 2023, the estimated forward annual dividend rate is 0.72 and the estimated forward annual dividend yield is 3.04%.
5. Ryman Hospitality Properties (RHP)
8% sales growth and 42.51% return on equity
Ryman Hospitality Properties, Inc. (NYSE: RHP) is a leading lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. The Company's core holdings* include a network of five of the top 10 largest non-gaming convention center hotels in the United States based on total indoor meeting space. These convention center resorts operate under the Gaylord Hotels brand and are managed by Marriott International. The Company also owns two adjacent ancillary hotels and a small number of attractions managed by Marriott International for a combined total of 10,110 rooms and more than 2.7 million square feet of total indoor and outdoor meeting space in top convention and leisure destinations across the country. The Company's Entertainment segment includes a growing collection of iconic and emerging country music brands, including the Grand Ole Opry; Ryman Auditorium, WSM 650 AM; Ole Red and Circle, a country lifestyle media network the Company owns in a joint-venture with Gray Television. The Company operates its Entertainment segment as part of a taxable REIT subsidiary. * The Company is the sole owner of Gaylord Opryland Resort & Convention Center; Gaylord Palms Resort & Convention Center; Gaylord Texan Resort & Convention Center; and Gaylord National Resort & Convention Center. It is the majority owner and managing member of the joint venture that owns the Gaylord Rockies Resort & Convention Center.
Earnings Per Share
As for profitability, Ryman Hospitality Properties has a trailing twelve months EPS of $4.05.
PE Ratio
Ryman Hospitality Properties has a trailing twelve months price to earnings ratio of 20.37. Meaning, the purchaser of the share is investing $20.37 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.51%.
